Milestone Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:MIST)

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) was the target of some unusual options trading on Monday. Investors purchased 3,255 call options on the stock. This represents an increase of 328% compared to the typical daily volume of 760 call options.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Millennium Management LLC acquired a new stake in shares of Milestone Pharmaceuticals in the third quarter valued at approximately $803,000. Boxer Capital Management LLC acquired a new stake in shares of Milestone Pharmaceuticals during the third quarter worth $1,333,000. Bank of America Corp DE lifted its stake in Milestone Pharmaceuticals by 200,550.0% during the third quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock valued at $32,000 after buying an additional 16,044 shares in the last quarter. Orbimed Advisors LLC purchased a new stake in shares of Milestone Pharmaceuticals in the 3rd quarter valued at approximately $6,444,000. Finally, Two Sigma Investments LP purchased a new stake in shares of Milestone Pharmaceuticals in the third quarter valued at $1,333,000. 86.18% of the stock is currently owned by institutional investors.

Milestone Pharmaceuticals Trading Down 1.5%

NASDAQ MIST opened at $2.65 on Wednesday. The company has a debt-to-equity ratio of 2.74, a quick ratio of 8.24 and a current ratio of 8.24. The firm has a market capitalization of $225.70 million, a price-to-earnings ratio of -3.23 and a beta of 0.41. The company’s 50 day moving average price is $2.08 and its 200 day moving average price is $1.84. Milestone Pharmaceuticals has a one year low of $0.63 and a one year high of $2.77.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.05. On average, sell-side analysts predict that Milestone Pharmaceuticals will post -0.62 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on MIST. Weiss Ratings restated a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a report on Monday. Wall Street Zen raised Milestone Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, November 23rd. Finally, Wells Fargo & Company began coverage on shares of Milestone Pharmaceuticals in a research report on Thursday, September 11th. They issued an “overweight” rating and a $4.00 price objective for the company. Two equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $4.50.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.